New Furan-Quinoline Compounds Designed and Tested as Powerful Tuberculosis Treatments

Compounds exhibited antitubercular activity with inhibition concentrations ranging from 1.6 to 12 µg/ml.

• The synthesized compounds inhibited the growth of the H37Rv strain of Mycobacterium tuberculosis.
• Molecular docking studies indicated that furan, quinoline, and diamide derivatives fit well within the binding domains of target proteins.
• Certain compounds, specifically 5f, 5b, and 8a, demonstrated particularly strong inhibition activity.
• The presence of three different chemical structures in these compounds may allow them to act on multiple targets.
• This research suggests potential pathways for novel drug discovery in tuberculosis treatment.

Simplified